#United States #New York #Inc. #Securities Fraud #Rosen Law Firm #Cassava Sciences

Cassava Sciences, Inc. Securities Fraud Lawsuit

In an important update for investors, the Rosen Law Firm, a renowned global law firm specializing in investor rights, is sending out a timely reminder to anyone who purchased securities of Cassava Sciences, Inc. (NASDAQ: SAVA) during the period from February 7, 2024, to November 24, 2024. This notification warns of a crucial deadline approaching on February 10, 2025, for those wishing to serve as lead plaintiffs in a securities fraud lawsuit.

Background on the Case

The lawsuit alleges that during the specified Class Period, Cassava Sciences misled investors regarding the potential of its primary drug candidate, simufilam. The firm's management purportedly portrayed confidence in the drug's efficacy while simultaneously downplaying risks associated with its development. As a result, investors were left with a misleading impression about the viability of simufilam in the treatment of Alzheimer’s Disease.

Once the true facts began to surface, including doubts surrounding the drug's effectiveness that had been masked under optimistic reports, the share value plummeted, leading to substantial losses for investors. Those who acquired Cassava securities based on the incorrect assurances are now encouraged to seek legal representation to recover their damages.

How to Join the Lawsuit

Anyone interested in joining the action is directed to visit Rosen Law Firm's website. They can also reach out directly to Phillip Kim, Esq. by calling 866-767-3653, or via email at [email protected]. Prospective class members should act promptly, as the lead plaintiff status is pivotal; it entails responsibilities as the representative for all affected investors.

Why Choose Rosen Law Firm?

Selecting the right counsel is critical for investors seeking redress in securities lawsuits. The Rosen Law Firm has proven experience and has successfully led many securities class actions. They've notably secured the largest settlement in a securities fraud case against a Chinese company at the time and have consistently ranked highly in terms of the number of settlements achieved. In 2019 alone, they recovered over $438 million for their clients.

Laurence Rosen, the firm's founding partner, has received accolades from various sources, including being recognized by Law360 for his prominent role as a Titan of the Plaintiffs' Bar. This pedigree of success makes them a formidable choice for leading this class action.

Key Considerations

Investors should keep a few essential points in mind:

• - No class has been formally certified yet; hence, all claimants should ensure they are adequately represented.
• - They have the option to either appoint their own counsel or remain passive participants without participating in the lawsuit.
• - The possibility of recovering damages may still exist even if one chooses not to become a lead plaintiff.

In the ever-evolving landscape of securities laws and investor rights, staying informed and acting swiftly is vital. Make your voice heard, and do not miss this opportunity to seek justice for potential misguided assurances from Cassava Sciences.

Stay updated by following updates from the Rosen Law Firm on LinkedIn, Twitter, or Facebook. The attorneys at the firm are prepared to navigate this challenging landscape on behalf of stakeholders who believe they have been wronged.